<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704128</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH3-RNI20-SESAME</org_study_id>
    <secondary_id>2020-A03435-34</secondary_id>
    <secondary_id>20.12.14.65838</secondary_id>
    <nct_id>NCT04704128</nct_id>
  </id_info>
  <brief_title>Identification of Pathophysiological Pathways and Therapeutic Targets in Primary Stomatodynia by Salivary Metabolomics</brief_title>
  <acronym>SESAME</acronym>
  <official_title>Identification de Voies Physiopathologiques et Cibles thérapeutiques Dans la Stomatodynie Primaire (&quot; Burning Mouth Syndrome &quot;) Par la métabolomique Salivaire : étude Cas/témoins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Burning mouth syndrome (BMS) is defined by a chronic oral pain affecting especially&#xD;
      postmenopausal women. Its physiopathology is still unknown and several hypotheses have been&#xD;
      put forward to explain this syndrome, such as neurological, hormonal or inflammatory process.&#xD;
      The recent development of salivary metabolomic profiling in oral diseases has led to the&#xD;
      identification of potential pathways in such disorders. The aim of this study is to analyze&#xD;
      the salivary metabolomic in BMS patients compared to healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Burning mouth syndrome (BMS) is defined by a chronic oral pain affecting especially&#xD;
      postmenopausal women. Its physiopathology is still unknown and several hypotheses have been&#xD;
      put forward to explain this syndrome, such as neurological, hormonal or inflammatory process.&#xD;
      The recent development of salivary metabolomic profiling in oral diseases has led to the&#xD;
      identification of potential pathways in such disorders. The aim of this study is to analyze&#xD;
      the salivary metabolomic in BMS patients compared to healthy controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Actual">May 12, 2021</completion_date>
  <primary_completion_date type="Actual">May 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative analysis of salivary metabolomic profiles between cases (primary BMS) and controls</measure>
    <time_frame>at inclusion</time_frame>
    <description>metabolites will be measured in saliva by chromatography-mass spectrometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative analysis of salivary neuropeptides between cases (primary BMS) and controls</measure>
    <time_frame>at inclusion</time_frame>
    <description>quantitative assessment of levels of neuropeptides (NGF, histamine, tryptase, kallicrein) will be assessed in saliva in cases and controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative analysis of salivary hormones between cases (primary BMS) and controls</measure>
    <time_frame>at inclusion</time_frame>
    <description>quantitative assessment of levels of steroid hormones (cortisol, 11-desoxycortisol, DHEA, SDHEA, progesterone, 17-hydroxyprogesterone, testosterone, androstenedione) will be assessed in saliva in cases and controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative analysis of salivary inflammatory cytokines between cases (primary BMS) and controls</measure>
    <time_frame>at inclusion</time_frame>
    <description>quantitative assessment of levels of cytokines (IL-2, IL-6, IL-18, TNFα) will be assessed in saliva in cases and controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between salivary biomarkers and pain characteristics</measure>
    <time_frame>at inclusion</time_frame>
    <description>metabolites profile, salivary neuropeptides, hormones and cytokines will be compared according to the category of pain (type I-II-III, neuropathic pain score DN4&gt;4)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">53</enrollment>
  <condition>Primary Burning Mouth Syndrome</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <description>women with primary stomatodynia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>women without oral disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Salivic sample</intervention_name>
    <description>Collection of total saliva not stimulated</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Regarding the high predominance of this pathology among women and in order to optimize the&#xD;
        study homogeneity, only women will be enrolled in this study.&#xD;
&#xD;
        In the control group, patients will be selected for having close characteristics with cases&#xD;
        (pairing for age +/- 5 years and for sex).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For cases : primary Burning Mouth Syndrome, based on the IHS diagnosis criteria&#xD;
&#xD;
          -  For cases : being able to realise the salivary collection&#xD;
&#xD;
          -  For controls : no primary BMS&#xD;
&#xD;
          -  For controls : being able to realise the salivary collection&#xD;
&#xD;
        Exclusion Criteria for both groups:&#xD;
&#xD;
          -  Treatment by antibiotics in the previous month&#xD;
&#xD;
          -  New treatment in the previous two weeks&#xD;
&#xD;
          -  Active smoking&#xD;
&#xD;
          -  Active infectious or inflammatory oral disease&#xD;
&#xD;
          -  Systemic disease that could have an impact on the salivary metabolome or on the&#xD;
             neurological system&#xD;
&#xD;
          -  Being under legal guardianship&#xD;
&#xD;
          -  Opposition to the processing of personal data&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahtab SAMIMI, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Hospital University of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Burning Mouth Syndrome</keyword>
  <keyword>Salivary metabolomic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burning Mouth Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

